Relexxii® (methylphenidate hydrochloride extended-release) – New drug approval
June 23, 2022 - The FDA approved Vertical Pharmaceuticals’ Relexxii (methylphenidate hydrochloride extended-release), for the treatment of attention deficit hyperactivity disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients 6 years of age and older.
Top